(CercleFinance.com) – GenSight Biologics strengthens its management team to support the launch of Lumevoq in Europe.
Philippe Motté is appointed Senior Vice-President, Regulatory Affairs and Quality, reporting to Bernard Gilly, Chief Executive Officer, and member of the Executive Committee.
Michiel Hemels is appointed Vice President, Pricing and Global Market Access, reporting to Sissel Rodahl, Senior Vice President, Commercial Operations.
‘ Philippe brings deep expertise in securing the regulatory journey and interacting with global regulatory authorities, while Michiel’s experience will be instrumental in access, pricing and reimbursement for LUMEVOQ and, more broadly, the wallet. of GenSight’, commented Bernard Gilly, CEO and co-founder of GenSight Biologics.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
